Even as the volume of mergers and acquisitions in 2019 reached the highest level in the last 10 years, multiple big pharma companies are looking to get smaller, spinning off units into separate entities.
Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.
Therapeutic area data reported by biopharma companies on phase III trials in January 2020, including: Abbvie, Astrazeneca, Beigene, Biofrontera, Eli Lilly, EMD Serono, Erytech, Evolus, Incyte, Innovent, Isofol Medical, Kala, Kyowa Kirin, Lipidor, Merck, Nucana, Orion, Rafael, Roche, Sellas Life Sciences, VBL, Verastem.
Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear. The price-weighted index returned 40% in value thanks to a steady flow of positive regulatory and clinical trial results from the companies throughout the year. However, investors may be less impressed with the start they have made this year, with the index dipping 8.4% in January.
RSS
